Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia

Luigi Ferini-Strambi, Mauro Manconi, Vincenza Castronovo, Laura Riva, Anna Bianchi

Research output: Contribution to journalArticle

Abstract

Antidepressants may have sleep and autonomic side-effects. The acute and long-term effect of reboxetine (2 mg b.i.d.) on sleep and cardiac autonomic activity was compared with that of placebo in a single-blind study. Twelve patients affected by dysthymia underwent four polysomnographic studies at baseline (placebo); at night 3 (reboxetine; acute effect); at night 9 (reboxetine; intermediate-term effect); and at night 122 (reboxetine; chronic effect). After the first administration, reboxetine increased time awake after sleep onset, number of awakenings, percentage of stages 1 and 2 non-rapid eye movement (REM), and reduced the amount of stages 3-4 non-REM, but all these effects disappeared by continuing treatment. However, reboxetine caused a persistent suppression of REM sleep, which was accompanied by an increase of REM sleep latency. The spectral analysis of heart rate variability showed a trend towards an increase in sympathetic activity with both acute and intermediate reboxetine use. Long-term treatment with 4 mg reboxetine does not cause significant changes in cardiac autonomic function.

Original languageEnglish
Pages (from-to)417-422
Number of pages6
JournalJournal of Psychopharmacology
Volume18
Issue number3
DOIs
Publication statusPublished - Sep 2004

Fingerprint

Sleep
REM Sleep
Eye Movements
Placebos
Autonomic Agents
Single-Blind Method
reboxetine
Antidepressive Agents
Heart Rate
Therapeutics

Keywords

  • Cardiac autonomic activity
  • Dysthymia
  • Insomnia
  • Polysomnography
  • Reboxetine
  • Sleep

ASJC Scopus subject areas

  • Pharmacology
  • Psychiatry and Mental health
  • Neuroscience(all)

Cite this

Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia. / Ferini-Strambi, Luigi; Manconi, Mauro; Castronovo, Vincenza; Riva, Laura; Bianchi, Anna.

In: Journal of Psychopharmacology, Vol. 18, No. 3, 09.2004, p. 417-422.

Research output: Contribution to journalArticle

Ferini-Strambi, Luigi ; Manconi, Mauro ; Castronovo, Vincenza ; Riva, Laura ; Bianchi, Anna. / Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia. In: Journal of Psychopharmacology. 2004 ; Vol. 18, No. 3. pp. 417-422.
@article{3bb4d7f0f96844f8bf244ec866c86405,
title = "Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia",
abstract = "Antidepressants may have sleep and autonomic side-effects. The acute and long-term effect of reboxetine (2 mg b.i.d.) on sleep and cardiac autonomic activity was compared with that of placebo in a single-blind study. Twelve patients affected by dysthymia underwent four polysomnographic studies at baseline (placebo); at night 3 (reboxetine; acute effect); at night 9 (reboxetine; intermediate-term effect); and at night 122 (reboxetine; chronic effect). After the first administration, reboxetine increased time awake after sleep onset, number of awakenings, percentage of stages 1 and 2 non-rapid eye movement (REM), and reduced the amount of stages 3-4 non-REM, but all these effects disappeared by continuing treatment. However, reboxetine caused a persistent suppression of REM sleep, which was accompanied by an increase of REM sleep latency. The spectral analysis of heart rate variability showed a trend towards an increase in sympathetic activity with both acute and intermediate reboxetine use. Long-term treatment with 4 mg reboxetine does not cause significant changes in cardiac autonomic function.",
keywords = "Cardiac autonomic activity, Dysthymia, Insomnia, Polysomnography, Reboxetine, Sleep",
author = "Luigi Ferini-Strambi and Mauro Manconi and Vincenza Castronovo and Laura Riva and Anna Bianchi",
year = "2004",
month = "9",
doi = "10.1177/026988110401800313",
language = "English",
volume = "18",
pages = "417--422",
journal = "Journal of Psychopharmacology",
issn = "0269-8811",
publisher = "SAGE Publications Ltd",
number = "3",

}

TY - JOUR

T1 - Effects of reboxetine on sleep and nocturnal cardiac autonomic activity in patients with dysthymia

AU - Ferini-Strambi, Luigi

AU - Manconi, Mauro

AU - Castronovo, Vincenza

AU - Riva, Laura

AU - Bianchi, Anna

PY - 2004/9

Y1 - 2004/9

N2 - Antidepressants may have sleep and autonomic side-effects. The acute and long-term effect of reboxetine (2 mg b.i.d.) on sleep and cardiac autonomic activity was compared with that of placebo in a single-blind study. Twelve patients affected by dysthymia underwent four polysomnographic studies at baseline (placebo); at night 3 (reboxetine; acute effect); at night 9 (reboxetine; intermediate-term effect); and at night 122 (reboxetine; chronic effect). After the first administration, reboxetine increased time awake after sleep onset, number of awakenings, percentage of stages 1 and 2 non-rapid eye movement (REM), and reduced the amount of stages 3-4 non-REM, but all these effects disappeared by continuing treatment. However, reboxetine caused a persistent suppression of REM sleep, which was accompanied by an increase of REM sleep latency. The spectral analysis of heart rate variability showed a trend towards an increase in sympathetic activity with both acute and intermediate reboxetine use. Long-term treatment with 4 mg reboxetine does not cause significant changes in cardiac autonomic function.

AB - Antidepressants may have sleep and autonomic side-effects. The acute and long-term effect of reboxetine (2 mg b.i.d.) on sleep and cardiac autonomic activity was compared with that of placebo in a single-blind study. Twelve patients affected by dysthymia underwent four polysomnographic studies at baseline (placebo); at night 3 (reboxetine; acute effect); at night 9 (reboxetine; intermediate-term effect); and at night 122 (reboxetine; chronic effect). After the first administration, reboxetine increased time awake after sleep onset, number of awakenings, percentage of stages 1 and 2 non-rapid eye movement (REM), and reduced the amount of stages 3-4 non-REM, but all these effects disappeared by continuing treatment. However, reboxetine caused a persistent suppression of REM sleep, which was accompanied by an increase of REM sleep latency. The spectral analysis of heart rate variability showed a trend towards an increase in sympathetic activity with both acute and intermediate reboxetine use. Long-term treatment with 4 mg reboxetine does not cause significant changes in cardiac autonomic function.

KW - Cardiac autonomic activity

KW - Dysthymia

KW - Insomnia

KW - Polysomnography

KW - Reboxetine

KW - Sleep

UR - http://www.scopus.com/inward/record.url?scp=6044246274&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=6044246274&partnerID=8YFLogxK

U2 - 10.1177/026988110401800313

DO - 10.1177/026988110401800313

M3 - Article

C2 - 15358987

AN - SCOPUS:6044246274

VL - 18

SP - 417

EP - 422

JO - Journal of Psychopharmacology

JF - Journal of Psychopharmacology

SN - 0269-8811

IS - 3

ER -